Home Dialysis Plus Secures Funding to Commercialize Medical Device

Financial Commitment to Fund the Commercialization of a Home Hemodialysis System

Home Dialysis Plus, Ltd. (HD+), a developer of devices and products for kidney dialysis, has secured a financial commitment to fund the commercialization of a new home hemodialysis system. HD+ recognizes the support of policymakers, local universities and institutions engaged in innovative solutions to healthcare as a precursor to this commercial investment.

“Today’s dialysis patients, doctors and providers are demanding improvements and cost-effective alternatives to standard treatment regimes,” said Michael Baker, CEO of HD+. “Thanks to a commitment to invest up to $50M by global private equity firm Warburg Pincus, we now have the ability to advance the HD+ technology in hopes of meeting that demand. It’s a privilege to have investors of this caliber supporting such an effort.”

“This is not only a tremendous victory for kidney dialysis patients and the cause of lowering the costs of health care, it is a victory for the ever-growing promise of nanoscience and microtechnology,” says Senator Ron Wyden. "This is an example of how targeted, smart public investment can trigger job-creating private investment in Oregon and beyond. HD+ is now poised to become a market leader in this medically-critical technology, and that can only help further establish Oregon’s reputation as a location of choice for nanoscience companies and capital.”

The commitment by Warburg Pincus will allow HD+ to further the development of a portable dialysis system that is intended to allow patients to experience the benefits of frequent dialysis, a treatment regime that more closely simulates natural kidney processes and has been shown to improve patients’ quality of life.

Currently, the standard of care for most patients is a series of four-hour treatments, three times per week at a dialysis clinic, a rigorous regime that can be both physiologically and emotionally taxing. The HD+ system is intended to offer a gentler treatment that will be easier on the patient and more affordable for dialysis providers.

As the recipients of this investment, HD+ credits Oregon Nanoscience and Microtechnologies Institute (ONAMI) and Oregon State Venture Fund for previous investments that propelled HD+ to an investor-ready position. The company has returned the favor by creating 30 new jobs within the region over the past four months.

No more results found.
No more results found.